Jiangao Fan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12041379/publications.pdf

Version: 2024-02-01

430874 454955 4,386 31 18 30 h-index citations g-index papers 31 31 31 5531 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 2022, 71, 1006-1019.	12.1	195
2	Serum creatinine levels and risk of nonalcohol fatty liver disease in a middleâ€aged and older Chinese population: A crossâ€sectional analysis. Diabetes/Metabolism Research and Reviews, 2022, 38, e3489.	4.0	8
3	Neck circumference as an independent predictor for NAFLD among postmenopausal women with normal body mass index. Nutrition and Metabolism, 2021, 18, 30.	3.0	10
4	Prolyl endopeptidase disruption reduces hepatic inflammation and oxidative stress in methionine-choline-deficient diet-induced steatohepatitis. Life Sciences, 2021, 270, 119131.	4.3	3
5	Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study. Frontiers in Cardiovascular Medicine, 2021, 8, 664583.	2.4	1
6	CD8+ T Cells Involved in Metabolic Inflammation in Visceral Adipose Tissue and Liver of Transgenic Pigs. Frontiers in Immunology, 2021, 12, 690069.	4.8	8
7	The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. Journal of Hepatology, 2021, 75, 454-461.	3.7	70
8	Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 320-325.	2.8	23
9	CREBZF as a Key Regulator of STAT3 Pathway in the Control of Liver Regeneration in Mice. Hepatology, 2020, 71, 1421-1436.	7.3	32
10	Chronic hepatitis B and nonâ€alcoholic fatty liver disease: Conspirators or competitors?. Liver International, 2020, 40, 496-508.	3.9	39
11	Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study. Cardiovascular Diabetology, 2020, 19, 209.	6.8	12
12	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	1.3	1,840
13	Hepatitis B-related glomerulonephritis and optimization of treatment. Expert Review of Gastroenterology and Hepatology, 2020, 14, 113-125.	3.0	7
14	Cytokines and Abnormal Glucose and Lipid Metabolism. Frontiers in Endocrinology, 2019, 10, 703.	3.5	152
15	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 2019, 69, 2672-2682.	7.3	1,203
16	CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis. Journal of Hepatology, 2018, 69, 705-717.	3.7	145
17	Asia–Pacific Working Party on Nonâ€alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 70-85.	2.8	358
18	Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH). Medical Science Monitor, 2018, 24, 6946-6967.	1.1	25

#	Article	IF	Citations
19	Impaired lung function is associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in middle-aged and elderly Chinese. BMC Endocrine Disorders, 2017, 17, 18.	2.2	21
20	Association of calf circumference with insulin resistance and non-alcohol fatty liver disease: the REACTION study. BMC Endocrine Disorders, 2017, 17, 28.	2.2	6
21	Type 2 diabetes and gender differences in liver cancer by considering different confounding factors: a meta-analysis of cohort studies. Annals of Epidemiology, 2016, 26, 764-772.	1.9	16
22	Type 2 diabetes mellitus and risk of gallbladder cancer: a systematic review and metaâ€analysis of observational studies. Diabetes/Metabolism Research and Reviews, 2016, 32, 63-72.	4.0	34
23	Circulating periostin in relation to insulin resistance and nonalcoholic fatty liver disease among overweight and obese subjects. Scientific Reports, 2016, 6, 37886.	3.3	22
24	Galanin receptor 2 mediates antifibrogenic effects of galanin on hepatic stellate cells. Experimental and Therapeutic Medicine, 2016, 12, 3375-3380.	1.8	7
25	Plasma selenium levels and nonalcoholic fatty liver disease in Chinese adults: a cross-sectional analysis. Scientific Reports, 2016, 6, 37288.	3.3	53
26	Plasma osteoprotegerin levels are inversely associated with nonalcoholic fatty liver disease in patients with type 2 diabetes: A case–control study in China. Metabolism: Clinical and Experimental, 2016, 65, 475-481.	3.4	19
27	Role of CTGF gene promoter methylation in the development of hepatic fibrosis. American Journal of Translational Research (discontinued), 2016, 8, 125-32.	0.0	9
28	Deregulated SLC2A1 Promotes Tumor Cell Proliferation and Metastasis in Gastric Cancer. International Journal of Molecular Sciences, 2015, 16, 16144-16157.	4.1	38
29	Association between nonalcoholic fatty liver disease and colorectal adenoma: a systematic review and meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 322-33.	1.3	23
30	Integrative analysis of the transcriptome and targetome identifies the regulatory network of miR-16: An inhibitory role against the activation of hepatic stellate cells. Bio-Medical Materials and Engineering, 2014, 24, 3863-3871.	0.6	7
31	Metabolic dysfunction-associated fatty liver disease: from basic research to clinical application. Chinese Medical Journal, 0, Publish Ahead of Print, .	2.3	O